StockData
GeneDx Holdings Corp. logo

GeneDx Holdings Corp. (WGS) stock

WGSNasdaqServices-Health ServicesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 6/3043% above fair value
$45.46−3.78 (-7.68%)

Close on Nov 20, 2026Market cap $1.36BP/E –Yield –

GeneDx free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

GeneDx's free cash flow for the twelve months ending Jun 30, 2026 was -$75.80M, down 9232.3% year over year. For fiscal 2025 it was $14.26M. The highest annual figure on record is $14.26M in fiscal 2025.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$14.26M–
FY2024Dec 31, 2024-$33.99M–
FY2023Dec 31, 2023-$185.40M–
FY2022Dec 31, 2022-$326.31M–
FY2021Dec 31, 2021-$199.83M–
FY2020Dec 31, 2020-$117.22M–
FY2019Dec 31, 2019-$30.65M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$39.10M-585.6%
Q1 FY2026Mar 31, 2026-$38.86M-1058.8%
Q4 FY2025Dec 31, 2025-$7.44M–
Q3 FY2025Sep 30, 2025$9.60M–
Q2 FY2025Jun 30, 2025$8.05M–
Q1 FY2025Mar 31, 2025$4.05M–
Q4 FY2024Dec 31, 2024-$6.23M–
Q3 FY2024Sep 30, 2024-$5.04M–
Q2 FY2024Jun 30, 2024-$5.86M–
Q1 FY2024Mar 31, 2024-$16.86M–
Q4 FY2023Dec 31, 2023-$32.23M–
Q3 FY2023Sep 30, 2023-$41.34M–
Q2 FY2023Jun 30, 2023-$56.26M–
Q1 FY2023Mar 31, 2023-$55.56M–
Q4 FY2022Dec 31, 2022-$66.82M–
Q3 FY2022Sep 30, 2022-$90.60M–
Q2 FY2022Jun 30, 2022-$86.02M–
Q1 FY2022Mar 31, 2022-$82.87M–
Q4 FY2021Dec 31, 2021-$57.04M–
Q3 FY2021Sep 30, 2021-$71.96M–
Q2 FY2021Jun 30, 2021-$26.55M–
Q1 FY2021Mar 31, 2021-$44.28M–
Q4 FY2020Dec 31, 2020-$25.12M–

More GeneDx figures

See a number that looks wrong?